Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina

The Pharmacogenomics Journal volume 17, pages 378–381 (2017)Cite this article

Subjects

Abstract

A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype: gUMs) was reported among Ashkenazi Jews (AJ) living in New York (USA) than in other North American Caucasians, which might be important to guide the prescription for CYP2D6 substrates in AJ communities around the world. This study was aimed to determine whether the high frequency of CYP2D6 gUMs described in AJ from USA was replicated in AJ from Argentina when compared with other multiethnic admixture Argentines (GA). The frequency of the most common allelic variants and of CYP2D6 gUMs (>2 active genes) and poor metabolizers (0 active genes, gPMs) was also compared among the studied Argentine populations. CYP2D6 genotyping was performed in 173 AJ and 246 GA DNA samples of unrelated donors from the metropolitan area of Buenos Aires. CYP2D6 alleles (*2, *3, *4, *5, *6, *10, *17, *35, *41 and multiple copies), genotypes and functional phenotype frequencies were determined. The frequencies of gUMs and gPMs in AJ from Argentina were 11.5% and 5.2%, respectively, whereas in GA, the frequencies of gUM and gPMs were 6.5% and 4.9%, respectively. Comparisons between AJ and GA showed that gUMs frequencies were twofold higher (P<0.05) in AJ than GA. CYP2D6*35 allele was more frequent in GA than AJ, whereas CYP2D6*41 and *1xN were more frequent in AJ than in GA (P<0.05). This study supports the previously reported high frequency of gUMs on another Ashkenazi population in New York. The present findings also support the interethnic variability of CYP2D6 genetic polymorphism in the overall Argentine population.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Owen RP, Sangkuhl K, Klein TE, Altman RB . Cytochrome P450 2D6. Pharmacogenet Genomics 2009; 19: 559–562.

    Article  CAS  Google Scholar 

  2. CYP2D6 allele nomenclature. [Online] Available at www.cypalleles.ki.se/cyp2d6.htm [accessed on 25 November 2015].

  3. LLerena A, Naranjo ME, Rodrigues-Soares F, Penas-LLedó EM, Fariñas H, Tarazona-Santos E . Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol 2014; 10: 1569–1583.

    Article  CAS  Google Scholar 

  4. LLerena A, Dorado P, Naranjo ME, Peñas-Lledó EM . CYP2D6 ethnic variability in Hispanics. In: Baumann P (ed). CYP2D6: Genetics, Pharmacology and Clinical Relevance. Future Medicine: London, UK, 2014 pp 54–66.

    Google Scholar 

  5. Sosa-Macias M, Moya GE, LLerena A, Ramírez R, Terán E, Peñas-LLedó EM et al. Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics 2015; 16: 673–676.

    Article  CAS  Google Scholar 

  6. Ostrer H . A genetic profile of contemporary Jewish populations. Nat Rev Genet 2001; 2: 891–898.

    Article  CAS  Google Scholar 

  7. Costa MD, Pereira JB, Pala M, Fernandes V, Olivieri A, Achilli A et al. A substantial prehistoric European ancestry amongst Ashkenazi maternal lineages. Nat Commun 2013; 4: 2543.

    Article  Google Scholar 

  8. Jmelnizky A, Erdei E . The Jewish Population in Buenos Aires: Sociodemographic Survey. AMIA: Buenos Aires, Argentina, 2005.

    Google Scholar 

  9. Behar DM, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J et al. The genome-wide structure of the Jewish people. Nature 2010; 466: 238–242.

    Article  CAS  Google Scholar 

  10. Ostrer H, Skorecki K . The population genetics of the Jewish people. Hum Genet 2013; 132: 119–127.

    Article  Google Scholar 

  11. Gross SJ, Pletcher BA, Monaghan KG . Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008; 10: 54–56.

    Article  Google Scholar 

  12. Tkatch R, Schwartz K, Shore RD, Penner LA, Simon MS, Albrecht TL . Breast cancer incidence rates among orthodox Jewish women. J Immigr Minor Health 2014; 16: 1007–1010.

    Article  Google Scholar 

  13. Zhang W, Hui KY, Gusev A, Warner N, Ng SM, Ferguson J et al. Extended haplotype association study in Crohn’s disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-κB pathway gene, HEATR3. Genes Immun 2013; 14: 310–316.

    Article  CAS  Google Scholar 

  14. Fletcher B, Goldstein DB, Bradman AL, Weale ME, Bradman N, Thomas MG . High-throughput analysis of informative CYP2D6 compound haplotypes. Genomics 2003; 81: 166–174.

    Article  CAS  Google Scholar 

  15. Luo HR, Aloumanis V, Lin KM, Gurwitz D, Wan YJ . Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics 2004; 4: 395–401.

    Article  CAS  Google Scholar 

  16. Nakai K, Habano W, Nakai K, Fukushima N, Suwabe A, Moriya S et al. Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci 2005; 78: 107–111.

    Article  CAS  Google Scholar 

  17. Scott SA, Edelmann L, Kornreich R, Erazo M, Desnick RJ . CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics 2007; 8: 721–730.

    Article  CAS  Google Scholar 

  18. Scott SA, Edelmann L, Kornreich R, Desnick RJ . Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008; 82: 495–500.

    Article  CAS  Google Scholar 

  19. Efrati E, Elkin H, Sprecher E, Krivoy N . Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Curr Drug Saf 2010; 5: 190–193.

    Article  CAS  Google Scholar 

  20. Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ . Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J 2012; 12: 297–305.

    Article  CAS  Google Scholar 

  21. Martis S, Peter I, Hulot JS, Kornreich R, Desnick RJ, Scott SA . Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J 2013; 13: 369–377.

    Article  CAS  Google Scholar 

  22. Martis S, Mei H, Vijzelaar R, Edelmann L, Desnick RJ, Scott SA . Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation. Pharmacogenomics J 2013; 13: 558–566.

    Article  CAS  Google Scholar 

  23. Yang Y, Peter I, Scott SA . Pharmacogenetics in Jewish populations. Drug Metabol Drug Interact 2014; 29: 221–233.

    Article  CAS  Google Scholar 

  24. Mirelman VA . Attitudes towards Jews in Argentina. Jew Soc Stud 1975; 37: 205–220.

    Google Scholar 

  25. LeElef N ‘World Jewish Population’. [Online] Available at http://www.simpletoremember.com/vitals/world-jewish-population.htm [accesssed on 22 October 2012].

  26. Dorado P, Heras N, Machín E, Hernández F, Terán E, LLerena A . CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur J Clin Pharmacol 2012; 68: 637–644.

    Article  Google Scholar 

  27. Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A . Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005; 39: 571–574.

    Article  Google Scholar 

  28. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234–242.

    Article  CAS  Google Scholar 

  29. Peñas-Lledó EM, Trejo HD, Dorado P, Ortega A, Hung H, Alonso E et al. CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients. Mol Psychiatry 2013; 18: 8–9.

    Article  Google Scholar 

  30. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351: 2827–2831.

    Article  CAS  Google Scholar 

  31. Peñas-Lledo EM, Dorado P, Aguera Z, Gratacós M, Estivill X, Fernández-Aranda F et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 2011; 16: 691–692.

    Article  Google Scholar 

  32. Peñas-Lledo EM, Blasco-Fontecilla H, Dorado P, Vaquero-Lorenzo C, Baca-García E, LLerena A . CYP2D6 and the severity of suicide attempts. Pharmacogenomics 2012; 13: 179–184.

    Article  Google Scholar 

  33. Peñas-Lledo E, Guillaume S, Naranjo ME, Delgado A, Jaussent I, Blasco-Fontecilla H et al. A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances. Pharmacogenomics J 2014; 15: 172–176.

    Article  Google Scholar 

  34. PharmaGKB dosing guideline CYP2D6. [Online] Available at https://www.pharmgkb.org/gene/PA128?tabType=tabVip#tabview=tab0&subtab=31 [accessed on 25 November 2015].

  35. Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015; 98: 127–134.

    Article  CAS  Google Scholar 

  36. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE et al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014; 95: 376–382.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by Gobierno de Extremadura, AEXCID 13IA001 (to Sociedad Iberoamericana de Farmacogenética y Farmacogenómica) and coordinated by the network Red Iberoamericana de Farmacogenética y Farmacogenómica (www.ribef.com).

Author information

Authors and Affiliations

  1. CICAB Clinical Research Center, Extremadura University and Medical School, Badajoz, Spain

    G Moya, P Dorado, M E G Naranjo, E M Peñas-Lledó & A LLerena

  2. Pontifical Catholic University of Argentina, Beunos Aires, Argentina

    G Moya

  3. Genos Laboratory, Buenos Aires, Argentina

    G Moya & V Ferreiro

  4. CIBERSAM, Madrid, Spain

    A LLerena

Authors
  1. G Moya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Dorado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V Ferreiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M E G Naranjo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E M Peñas-Lledó
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A LLerena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A LLerena.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moya, G., Dorado, P., Ferreiro, V. et al. High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina. Pharmacogenomics J 17, 378–381 (2017). https://doi.org/10.1038/tpj.2016.27

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2016.27

Search

Advanced search

Quick links